stockrow
Saturday 7 November 2026
Export BYSI’s income statement to Excel — free account
BeyondSpring Inc.
BYSI Healthcare Biotechnology
BeyondSpring Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.4 million.
- EPS
- +50.0%
- Free cash flow
- +35.8%
Quarter to June 2026, against a year earlier
0.61
0.02
−3.17%
Follow BYSI
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
2.05% | 5.26% | 35.53% | 24.96% | |
| (2.37%) | (3.34%) | (27.53%) | (29.29%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(5.11%) | (13.46%) | (594.25%) | 160.93% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.33) | (0.49) | (0.46) | (0.41) | |
Free Cash Flow |
(13.36) | (19.82) | (18.85) | (16.75) | |
Capital Expenditures |
(0.08) | (0.05) | — | — | |
| Other line items | |||||
Cash ROIC |
185.92% | 173.41% | 83.80% | 56.77% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.13 | 0.01 | 0.03 | 0.04 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
22.21 | 19.65 | 2.47 | 2.51 | |
Depreciation/Fixed assets |
1.43 | 0.52 | 0.17 | (0.27) | |
Capex/Depreciation |
(0.29) | (0.57) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.33) | (0.49) | (0.46) | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026